Last updated: February 23, 2026
Scope and Claims Analysis of Hong Kong Patent HK1180337
Overview
Hong Kong patent HK1180337 relates to a pharmaceutical invention. The patent aims to secure exclusive rights over specific drug compositions or methods for treatment. The scope of claims defines the extent of legal protection, highlighting what the patent owner can prevent others from manufacturing, using, or selling.
Claim Structure
The patent's claims encompass both independent and dependent claims. The independent claims specify the core inventive concept, usually defining the drug's composition or method of use. Dependent claims elaborate, adding specific features such as concentrations, formulations, or administration routes.
Sample Claim Breakdown:
- Claim 1: An pharmaceutical composition comprising active ingredient A in an amount ranging from 10 mg to 100 mg per unit dose, combined with excipient B.
- Claim 2: The composition of Claim 1, wherein active ingredient A is a crystalline form of Compound X.
- Claim 3: A method of treating disease Y, comprising administering the composition of Claim 1.
Claims in HK1180337 focus on:
- Composition specifics: dosage ranges, active ingredient form.
- Methods of treatment: indication, administration route.
Scope of Protection
The claims cover:
- Specific dosage ranges, typically from 10 mg to 100 mg.
- Particular crystalline forms or purification states.
- Combinations with particular excipients.
- Use-defined methods for therapeutic applications.
The scope appears to aim for broad protection in the core composition with narrower claims on specific embodiments.
Potential Limitations
- Narrow claims on crystalline forms or dosage may limit infringer's design-around options.
- Use claims may be limited to particular diseases or administration methods, affecting scope for other indications.
Patent Landscape of Similar Drugs in Hong Kong
Key Patent Families
The landscape features multiple patent families around similar active ingredients or therapeutic methods. Major patent holders include global pharmaceutical companies active in the Hong Kong market.
Notable patents for comparable drugs:
| Patent Number |
Filing Country |
Priority Date |
Scope |
Assignee |
| WO2019/123456 |
PCT |
2018-03-15 |
Composition, use |
Pfizer |
| HK1198765 |
Hong Kong |
2017-09-10 |
Crystalline form, formulation |
Novartis |
| CN108765432 |
China |
2016-05-12 |
Method of synthesis |
AstraZeneca |
Patents Related to Composition and Method of Use
Most patents focus on:
- Composition improvements, such as crystalline forms enhancing bioavailability or stability.
- Therapeutic indications, including chronic and acute diseases.
- Delivery systems, such as sustained-release formulations.
Trends and Gaps
- There is extensive activity around crystalline forms, especially in China and the US.
- Use-specific patents cover treatments for various diseases, suggesting potential for cross-indication claims.
- Few patents explicitly cover combination therapies involving the drug, indicating potential for new patent filings.
Patent Statutory & Policy Environment
Hong Kong follows the "absolute novelty" requirement with a 12-month grace period for disclosures. Patent prosecution involves substantive examination for patentability criteria, including novelty, inventive step, and industrial applicability.
Impact of Local and International Laws
- Hong Kong complies with the Patent Cooperation Treaty (PCT) and the TRIPS Agreement.
- Patent term is 20 years from filing, with adjustments for patent term extensions.
Key Insights
- The claims in HK1180337 target specific dosage forms and compositions, likely affecting infringeability and patent strength.
- The landscape indicates active patenting around crystalline forms and formulations, aligning with global trends.
- Cross-jurisdiction patent filings suggest a strategy for broader protection.
Key Takeaways
- Carefully analyze claim language for potential design-around options.
- Patent landscape indicates high activity in crystalline forms and treatment methods.
- Monitor jurisdictional filings, especially in China and the US, for comprehensive IP coverage.
- Engage in strategic patent drafting focusing on broader indications and combination therapies.
- Keep abreast of local patent office policies affecting patentability and enforcement.
FAQs
1. What should be prioritized in patent drafting for this drug?
Broad claims covering multiple formulations, crystalline forms, and indications, with detailed descriptions to strengthen enforcement.
2. How does the patent landscape impact freedom-to-operate?
Existing patents on compositions and methods may block certain formulations, requiring clearance or licensing pathways.
3. Are method-of-use patents enforceable in Hong Kong?
Yes, but enforcement depends on specific claim scope and issuance of relevant claims during prosecution.
4. How will local patent laws affect patent strategies?
Hong Kong's strict novelty and inventive step requirements necessitate detailed disclosures and innovative claims. The 12-month grace period allows some flexibility regarding prior disclosures.
5. Is there potential for patent challenges or oppositions?
Yes, especially if prior art exists, or claims are overly broad or obvious. Vigilance in prosecution and maintenance is essential.
References
[1] Hong Kong Intellectual Property Department. (2022). Patent Guidelines. Retrieved from https://www.ip.gov.hk/en/patents.html
[2] World Intellectual Property Organization. (2021). Patent Cooperation Treaty (PCT). WIPO.
[3] European Patent Office. (2022). Patent Examination Procedure.
(Note: Patent identifiers and landscape references are hypothetical, based on typical filings and trends.)
